Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response to recombinant zoster vaccine in immunosuppressed patients with rheumatic diseases
2024-518190-34-00Phase 4Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of Zoster vaccine recombinant in herpes zoster (HZ) (3 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoints: Geometric mean titer of gE-specific IgG at day 90 and gE-specific polyfunctional CD4-positive T-cell response at day 90. Planned start Feb 2026; status: authorised.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2024-518190-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518190-34-00.